Navigation Links
Cell Biosciences Strengthens Management Team
Date:7/3/2008

PALO ALTO, Calif., July 3 /PRNewswire/ -- Cell Biosciences, Inc., a provider of ultrasensitive protein detection and characterization systems to life science researchers, today announced three key management team additions.

Jason Novi was named Chief Financial Officer, with responsibility for the finance, manufacturing and administrative functions. Prior to joining Cell Biosciences, Mr. Novi was the Vice President, Finance at Nektar Therapeutics. He served as Director of Finance at Molecular Devices Corporation from 2000 to 2007, where he was responsible for all worldwide accounting, finance and treasury functions, and played a key role in the execution and integration of its corporate development activities.

Robert Gavin was named Vice President, Engineering. Mr. Gavin brings nearly 20 years of experience to the Cell Biosciences development team. Most recently, he served as Director of Engineering at MDS Analytical Technologies (previously Molecular Devices), where he directed multidisciplinary teams of mechanical, electrical, firmware, and systems engineers. Mr. Gavin has a strong record of creating highly-successful laboratory systems, including industry-leading optical plate readers and high throughput screening platforms.

Also announced was the appointment of Wilhelm Lachnit, Ph.D. as Vice President, Research and Development. Dr. Lachnit has two decades of experience in pharma/biotech and life sciences. Most recently, he held both scientific and commercial leadership positions at Molecular Devices, where he played a central role in the development and launch of the IonWorks(TM) product line. Previously, he pioneered the early adoption of automated cell-based assays at Roche and Syntex (acquired by Roche). Dr. Lachnit holds a Ph.D. in Pharmacology-Toxicology from the University of California, Davis.

"I am extremely pleased to announce these additions to the Cell Biosciences leadership team," said Tim Harkness, President and Chief Executive Officer. "These individuals have all been key contributors at successful life science companies. I am confident that they will provide exceptionally strong leadership as we develop our portfolio of ultrasensitive nano-proteomics products."

About Cell Biosciences

Cell Biosciences is a private life sciences company focused on nano-proteomics. We are developing instrumentation systems to enable the detection and characterization of specific proteins in extremely small biological samples. Our company's lead product, the Firefly 3000, is a capillary-based nanofluidic immunoassay platform designed for ultrasensitive detection and characterization of proteins. Cell Biosciences is located in Palo Alto, CA. http://www.cellbiosciences.com


'/>"/>
SOURCE Cell Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
Breaking Biology News(10 mins):